Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2020; 120(06): 899-911
DOI: 10.1055/s-0040-1710314
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

Roisin Bavalia
1   Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
,
Saskia Middeldorp
1   Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
,
Gerhard Weisser
2   Section of Angiology, Center of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany
,
Christine Espinola-Klein
2   Section of Angiology, Center of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany
› Author Affiliations
Further Information

Publication History

18 December 2019

25 March 2020

Publication Date:
03 June 2020 (online)

Also available at
   Permissions and Reprints

Abstract

As a result of the successful completion of their respective phase III studies compared with vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE). These DOACs—apixaban, dabigatran, edoxaban, and rivaroxaban—have subsequently seen a steady uptake among clinicians since their approval. Despite the suitability of DOACs for a broad range of patients, they are not appropriate in certain situations, whereas in others they require additional considerations such as dose reductions. Subanalyses of phase III trials and studies on specific VTE patient populations have been conducted to evaluate the safety and efficacy of the DOACs in a broad range of settings, such as patients with renal impairment, patients with cancer, patients of childbearing potential, patients with multiple comorbidities and pediatric patients. Furthermore, many recent guidance documents from important hematological societies and other specialists have incorporated several of these developments. These documents also identify the patients for whom DOACs are not suitable and where traditional anticoagulation options such as heparins or VKAs should be considered instead. This review provides an overview of key VTE patient subgroups, the clinical evidence supporting the use of anticoagulation in these patients, and a discussion of the most appropriate approaches to their management, including considerations such as dosing, acute and extended treatment durations, and DOAC selection.

Keywords

comorbidities - direct oral anticoagulants - special populations - venous thromboembolism
 

  • References

  • 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 2 Bristol-Myers Squibb. Pfizer. Eliquis® (apixaban) Summary of Product Characteristics. 2019 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf . Accessed December 24, 2019
    PubMedGoogle Scholar
  • 3 Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. 2019 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf . Accessed August 29, 2019
    PubMedGoogle Scholar
  • 4 Daiichi Sankyo Europe Gmb H. Lixiana® (edoxaban) Summary of Product Characteristics. 2019 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf . Accessed December 24, 2019
    PubMedGoogle Scholar
  • 5 Bayer AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2019 . Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf . Accessed December 24, 2019
    PubMedGoogle Scholar
  • 6 Ageno W, Haas S, Weitz JI. , et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: The GARFIELD-VTE registry. Thromb Haemost 2019; 119 (02) 319-327
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Konstantinides SV, Meyer G, Becattini C. , et al. ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 8 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 9 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 10 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 11 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 12 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 13 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 14 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 15 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 16 Paravattil B, Elewa H. Approaches to direct oral anticoagulant selection in practice. J Cardiovasc Pharmacol Ther 2018; 24: 1074248418793137
    PubMedGoogle Scholar
  • 17 Portola Pharmaceuticals Inc. BEVYXXA® (betrixaban) Prescribing Information. 2017 . Available at: https://www.bevyxxa.com/wp-content/uploads/2017/11/bevyxxa-betrixaban-capsules-prescribing-information-pdf . Accessed August 12, 2019
    PubMedGoogle Scholar
  • 18 Tsiara S, Pappas K, Boutsis D, Laffan M. New oral anticoagulants: should they replace heparins and warfarin?. Hellenic J Cardiol 2011; 52 (01) 52-67
    PubMedGoogle Scholar
  • 19 Bristol-Myers Squibb. Coumadin (warfarin sodium) Prescribing Information. 2017 . Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf . Accessed August 12, 2019
    PubMedGoogle Scholar
  • 20 Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 2014; 14 (03) 175-189
    CrossrefPubMedGoogle Scholar
  • 21 Douketis JD, Spyropoulos AC, Duncan J. , et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
    CrossrefPubMedGoogle Scholar
  • 22 Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41 (01) 206-232
    CrossrefPubMedGoogle Scholar
  • 23 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    PubMedGoogle Scholar
  • 24 Ageno W, Mantovani LG, Haas S. , et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12-e21
    PubMedGoogle Scholar
  • 25 Boehringer Ingelheim International GmbH. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003986/WC500197462.pdf . Accessed December 12, 2019
    PubMedGoogle Scholar
  • 26 Portola Pharmaceuticals Inc. ANDEXXA® (andexanet alfa) Prescribing Information. 2018 . Available at: https://www.portola.com/wp-content/uploads/Andexxa-prescribing-information-pdf.pdf . Accessed August 12, 2019
    PubMedGoogle Scholar
  • 27 European Medicines Agency. Press release: First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban. 2019 . Available at: https://www.ema.europa.eu/en/news/first-antidote-reversal-anticoagulation-factor-xa-inhibitors-apixaban-rivaroxaban . Accessed August 12, 2019
    PubMedGoogle Scholar
  • 28 Böttger B, Wehling M, Bauersachs RM. , et al. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients. Thromb Res 2014; 134 (05) 1014-1019
    CrossrefPubMedGoogle Scholar
  • 29 Gremmel T, Niessner A, Domanovits H. , et al. Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. Wien Klin Wochenschr 2018; 130 (23-24): 722-734
    CrossrefPubMedGoogle Scholar
  • 30 Ocak G, Lijfering WM, Verduijn M. , et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. J Thromb Haemost 2013; 11 (04) 627-633
    CrossrefPubMedGoogle Scholar
  • 31 Bauersachs RM, Lensing AWA, Prins MH. , et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014; 12: 25-32
    CrossrefPubMedGoogle Scholar
  • 32 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
    CrossrefPubMedGoogle Scholar
  • 33 Goldhaber SZ, Schulman S, Eriksson H. , et al. Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost 2017; 117 (11) 2045-2052
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014; 12: 21
    CrossrefPubMedGoogle Scholar
  • 35 Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis 2017; 11 (09) 243-256
    CrossrefPubMedGoogle Scholar
  • 36 Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis 2017; 10: 135-143
    CrossrefPubMedGoogle Scholar
  • 37 Posch F, Ay C, Stöger H, Kreutz R, Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost 2019; 3 (02) 207-216
    CrossrefPubMedGoogle Scholar
  • 38 Key NS, Khorana AA, Kuderer NM. , et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
    PubMedGoogle Scholar
  • 39 Farge D, Frere C, Connors JM. , et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 40 Meyer G, Marjanovic Z, Valcke J. , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
    CrossrefPubMedGoogle Scholar
  • 41 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 42 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (04) 389-396
    CrossrefPubMedGoogle Scholar
  • 43 Hull RD, Pineo GF, Brant RF. , et al; LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120 (01) 72-82
    CrossrefPubMedGoogle Scholar
  • 44 Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis 2017; 43 (04) 514-518
    CrossrefPubMedGoogle Scholar
  • 45 Imberti D, Cimminiello C, Di Nisio M, Marietta M, Polo Friz H, Ageno W. Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opin Pharmacother 2018; 19 (11) 1177-1185
    CrossrefPubMedGoogle Scholar
  • 46 Khorana AA, Yannicelli D, McCrae KR. , et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. Thromb Res 2016; 145: 51-53
    CrossrefPubMedGoogle Scholar
  • 47 Khorana A, McCrae K, Milentijevic D. , et al. Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population. Circulation 2017; 136 Abstract 15539
    PubMedGoogle Scholar
  • 48 Khorana AA, McCrae KR, Milentijevic D. , et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost 2017; 1 (01) 14-22
    CrossrefPubMedGoogle Scholar
  • 49 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 50 Di Nisio M, van Es N, Carrier M. , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019; 17 (11) 1866-1874
    CrossrefPubMedGoogle Scholar
  • 51 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 52 McBane II RD, Wysokinski WE, Le-Rademacher JG. , et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedGoogle Scholar
  • 53 Khorana AA, Noble S, Lee AYY. , et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1891-1894
    CrossrefPubMedGoogle Scholar
  • 54 National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease, version 1.2019. Plymouth Meeting, PA, USA: National Comprehensive Cancer Network, Inc. 2019 . Available at: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf . Accessed August 12, 2019
    PubMed
  • 55 Cohen AT, Maraveyas A, Beyer-Westendorf J. , et al. Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer. Ann Oncol 2019; 30: v724-725
    PubMedGoogle Scholar
  • 56 Picker N, Cohen AT, Maraveyas A. , et al. Patient preferences regarding anticoagulation therapy in patients with cancer having a VTE event - a Discrete Choice Experiment in the COSIMO study. Blood 2019; 134 (Suppl. 01) 2159
    PubMedGoogle Scholar
  • 57 Agnelli G, Becattini C, Bauersachs R. , et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost 2018; 118 (09) 1668-1678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Assistance Publique – Hôpitaux de Paris. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). 2018 . Available at: https://clinicaltrials.gov/ct2/show/NCT02746185 . Accessed August 12, 2019
    PubMed
  • 59 AIO-Studien-gGmbH. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. 2018 . Available at: https://clinicaltrials.gov/ct2/show/study/NCT02583191 . Accessed August 12, 2019
    PubMed
  • 60 Khorana AA, Soff GA, Kakkar AK. , et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
    CrossrefPubMedGoogle Scholar
  • 61 Carrier M, Abou-Nassar K, Mallick R. , et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
    CrossrefPubMedGoogle Scholar
  • 62 Cohen AT, Gitt AK, Bauersachs R. , et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017; 117 (07) 1326-1337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117 (01) 93-102
    CrossrefPubMedGoogle Scholar
  • 64 Shariff N, Aleem A, Levin V. , et al. Venous thromboembolism in patients with heart failure: in-hospital and chronic use of anti-coagulants for prevention. Recent Pat Cardiovasc Drug Discov 2012; 7 (01) 53-58
    CrossrefPubMedGoogle Scholar
  • 65 Prins MH, Lensing AWA, Bauersachs R. , et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
    CrossrefPubMedGoogle Scholar
  • 66 Vanassche T, Verhamme P, Wells PS. , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res 2018; 162: 7-14
    CrossrefPubMedGoogle Scholar
  • 67 von Vajna E, Alam R, So TY. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol Ther 2016; 5 (01) 19-41
    CrossrefPubMedGoogle Scholar
  • 68 Monagle P, Chan AKC, Goldenberg NA. , et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (02) e737S-e801S
    CrossrefPubMedGoogle Scholar
  • 69 Jaffray J, Young G. Deep vein thrombosis in pediatric patients. Pediatr Blood Cancer 2018; 65 (03) e26881
    CrossrefPubMedGoogle Scholar
  • 70 Halton JM, Lehr T, Cronin L. , et al. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost 2016; 116 (03) 461-471
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Halton JML, Albisetti M, Biss B. , et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost 2017; 15 (11) 2147-2157
    CrossrefPubMedGoogle Scholar
  • 72 Halton JML, Picard AC, Harper R. , et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism. Thromb Haemost 2017; 117 (11) 2168-2175
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Monagle P, Lensing AWA, Thelen K. , et al; EINSTEIN-Jr Phase 2 Investigators. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol 2019; 6 (10) e500-e509
    CrossrefPubMedGoogle Scholar
  • 74 Albisetti M, Biss B, Bomgaars L. , et al. Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Res Pract Thromb Haemost 2018; 2 (02) 347-356
    CrossrefPubMedGoogle Scholar
  • 75 Albisetti M, Brandão L, Bomgaars L. , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboemboism in paediatric patients: results of the DIVERSITY trial. ISTH Congress. Melbourne, Australia, 6–10 July 2019 , Abstract OC 57.3. Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01968246/full . Accessed April 13, 2020
    PubMed
  • 76 Luciani M, Albisetti M, Biss B. , et al. Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. Res Pract Thromb Haemost 2018; 2 (03) 580-590
    CrossrefPubMedGoogle Scholar
  • 77 Brandão L, Albisetti M, Halton J. , et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood 2020;135(7):491–504
    PubMed
  • 78 Bayer, Janssen Research & Development LLC. EINSTEIN Junior: oral rivaroxaban in children with venous thrombosis (EINSTEIN Jr). 2018 . Available at: https://clinicaltrials.gov/ct2/show/NCT02234843 . Accessed August 12, 2019
    PubMed
  • 79 Male C, Lensing AWA, Kubitza D. , et al. Rivaroxaban for the treatment of acute venous thromboembolism in children. ISTH Congress. Melbourne, Australia, 6–10 July 2019 , Abstract LB 01.5. Available at: https://isthcongressdaily.org/rivaroxaban-for-the-treatment-of-acute-venous-thromboembolism-in-children/ . Accessed April 13, 2020
    PubMed
  • 80 Pfizer B-MS. Apixaban for the acute treatment of venous thromboembolism in children. 2019 . Available at: https://clinicaltrials.gov/ct2/show/NCT02464969 . Accessed August 27, 2019
    PubMedGoogle Scholar
  • 81 Daiichi Sankyo Inc. Phase 1 pediatric pharmacokinetics/pharmacodynamics (PK/PD) study. 2019 . Available at: https://clinicaltrials.gov/ct2/show/NCT02303431 . Accessed August 12, 2019
    PubMed
  • 82 Daiichi Sankyo Inc. Hokusai study in pediatric patients with confirmed venous thromboembolism (VTE). 2019 . Available at: https://clinicaltrials.gov/ct2/show/study/NCT02798471 . Accessed August 27, 2019
    PubMed
  • 83 Gibson CM, Mehran R, Bode C. , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
    CrossrefPubMedGoogle Scholar
  • 84 Bates SM, Rajasekhar A, Middeldorp S. , et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
    CrossrefPubMedGoogle Scholar
  • 85 Martinelli I, Lensing AWA, Middeldorp S. , et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127 (11) 1417-1425
    CrossrefPubMedGoogle Scholar
  • 86 Scheres LJJ, Bistervels IM, Middeldorp S. Everything the clinician needs to know about evidence-based anticoagulation in pregnancy. Blood Rev 2019; 33: 82-97
    CrossrefPubMedGoogle Scholar
  • 87 Brekelmans MP, Scheres LJ, Bleker SM. , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017; 117 (04) 809-815
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Prandoni P, Noventa F, Ghirarduzzi A. , et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
    CrossrefPubMedGoogle Scholar
  • 89 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 90 Becattini C, Agnelli G, Schenone A. , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 91 Brighton TA, Eikelboom JW, Mann K. , et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    CrossrefPubMedGoogle Scholar
  • 92 Prandoni P, Lensing AWA, Prins MH. , et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res 2018; 168: 121-129
    CrossrefPubMedGoogle Scholar